A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 7 Drugs Hit 100 Billion Yen Mark in FY2022 Japan Sales, Largest Number in 17 Years
July 24, 2023
-
BUSINESS Sosei to Acquire Idorsia’s Japan and Korea Arms for 65 Billion Yen
July 21, 2023
-
ORGANIZATION JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
-
ORGANIZATION Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
-
BUSINESS Heavy Demand Triggers Shipment Curb for High-Dose Mounjaro Just 1 Month after Launch
July 20, 2023
-
BUSINESS Astellas Becomes 1st Japan Pharma to Sue US Govt over IRA
July 19, 2023
-
REGULATORY Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
July 18, 2023
-
BUSINESS Gilead Japan Building Sales Force to Prep for Full Oncology Entry: Chief
July 14, 2023
-
REGULATORY Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
July 13, 2023
-
BUSINESS Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
-
REGULATORY MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
-
BUSINESS Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
-
ORGANIZATION Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
-
REGULATORY PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
-
BUSINESS Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
-
BUSINESS FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
-
REGULATORY Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
REGULATORY Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
BUSINESS Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
-
BUSINESS Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…